Metabolic Responses of Metformin and Genetic Polymorphisms of SLC22A1 Gene in PCOS

Launched by BANGABANDHU SHEIKH MUJIB MEDICAL UNIVERSITY, DHAKA, BANGLADESH · Jan 9, 2023

Keywords

ClinConnect Summary

This clinical trial is studying how metformin, a medication often used to treat diabetes, affects women with polycystic ovary syndrome (PCOS) and whether certain genetic factors influence this response. The researchers want to understand how specific variations in a gene called SLC22A1 might affect how well metformin works in improving metabolic health in women aged 18 to 35 who have been newly diagnosed with PCOS.

To participate in this study, women must meet certain criteria, such as being newly diagnosed with PCOS and not having other specific health issues like diabetes or thyroid disorders. Participants will receive metformin and will have several check-ups over 24 weeks, during which they will provide blood samples to measure different health markers. This trial is being conducted at Bangabandhu Sheikh Mujib Medical University from February 2023 to September 2024, and it aims to help improve the understanding of how genetics can affect treatment for PCOS. If you’re interested in joining, make sure to discuss this with your healthcare provider for more information.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • • Newly diagnosed women of reproductive age (18 - 35 years) PCOS patients
• Exclusion Criteria:
• • • Patients having known similar endocrine disorders (hypothyroidism, hyperprolactinemia, androgen producing tumor, congenital adrenal hyperplasia, etc)
• • Planning to conceive within next six months, pregnant/ lactating mother
• • Patients with known diabetes mellitus, ischemic heart disease, chronic liver (serum ALT \>2 × upper limit of normal) and renal disease (eGFR \<60 ml/minute/1.73 m2 body surface area)
• • Patients taking oral contraceptive, steroid or drugs affecting insulin resistance (metformin, pioglitazone)